Neuroscientific Biopharmaceuticals CEO and MD Matthew Liddelow says the company has entered one of the most exciting stages of its existence – successfully transitioning into clinical trials for its lead drug, peptide based compound, EmtinB, which the company hopes will become a key treatment therapy for neurodegenerative conditions like Multiple Sclerosis and Alzheimer’s disease.

“The development of effective treatments for the vast majority of neurodegenerative conditions is limited by inadequate characterisation of these diseases – many questions regarding the direct causes remain unanswered,” he said.

“Instead of focusing on assumed processes of the disease itself, Neuroscientific Biopharmaceuticals (ASX:NSB) is developing a potential solution by targeting the cells that are directly affected by these diseases and stimulating survival mechanisms that allow the affected cells to withstand the damaging consequences of these diseases.

“EmtinB has the potential to address this unmet medical need, with the drug’s novel mode of action harnessing the body’s own defence mechanisms to combat the progression of these neurodegenerative conditions.”

And now the early-phase clinical trial for EmtinB underway, with Human Research Ethics Committee (HREC) approval for its Phase I clinical trial pending.

“NSB expects to achieve a number of key milestones during the 2H CY2022,” Liddelow said.

Early-Phase Clinical Trial underway

Recruitment started in late June 2022 for Early-Phase Clinical Trial, which aims to develop biomarker data from human blood samples.

This is expected to indicate proof of the mechanism of activity of EmtinB in humans for the purpose of guiding efficacy outcomes during future clinical trials in patients.

NSB also submitted its Phase I clinical trial for HREC review in early-July this year, and achieving approval to commence the Phase I clinical trial will be another key milestone for the company,” Liddelow says.

Positive results in multiple sclerosis animal studies

NSB is also undertaking animal studies in industry gold-standard models for multiple sclerosis, and have already reported very promising preliminary results from one study.

“These studies aim to characterise the treatment effect of EmtinB in models that represent the different stages of MS, such as the relapse-remitting stage and the more advanced progressive stage of MS,” Liddelow says.

“Essentially, we are hoping to see significant differences in a range of measures that equate to slowing the progression of the disease.”

These studies will be undertaken during the 2H of CY2022.

 This article was developed in collaboration with Neuroscientific Biopharmaceuticals Limited, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.